Study guide
2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease
WHNP-BC Women's Health Nurse Practitioner Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction: About the WHNP-BC Exam
WHNP-BC Exam Facts, Blueprint & Study Plan
2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening
1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening
3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention
2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites
4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers
3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers
5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility
4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies
6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy
5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion
7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health
6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis
8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care
7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction
9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care
8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy
10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth
9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency
11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions
10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn
12 Chapter 11: Intrapartum Principles & Fetal Surveillance
11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies
13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications
12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs
14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions
13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold
15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders
14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders
16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health
15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis
17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care
16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care
18 Chapter 17: Assessment, Diagnostic Testing & Interpretation
17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities
19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing
18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation
20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities
19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care
2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease
Key Takeaways Explain This Topic AI
Chlamydia trachomatis first-line therapy is oral doxycycline 100 mg twice daily for 7 days; azithromycin 1 g single dose is strictly reserved for pregnant patients or severe adherence barriers.
Neisseria gonorrhoeae is treated with ceftriaxone 500 mg intramuscular monotherapy for patients weighing under 150 kg (1 g for ≥150 kg), adding doxycycline only if chlamydial infection has not been ruled out.
Primary, secondary, and early latent syphilis are treated with benzathine penicillin G 2.4 million units IM single dose, whereas late latent syphilis requires weekly doses for 3 consecutive weeks.
Penicillin is the only proven curative agent for syphilis during pregnancy; pregnant women with documented severe penicillin allergy must undergo hospital desensitization followed by benzathine penicillin G.
Pelvic inflammatory disease requires immediate empiric treatment upon identifying at least one minimum bimanual sign (uterine, adnexal, or cervical motion tenderness) using ceftriaxone 500 mg IM plus oral doxycycline and metronidazole for 14 days.
Last updated: October 2026
Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & PID
Sexually transmitted infections (STIs) and pelvic inflammatory disease (PID) represent crucial priorities in ambulatory women's health. Prompt detection and guideline-adherent pharmacotherapy prevent long-term reproductive complications, including tubal factor infertility, ectopic pregnancy, and chronic pelvic pain. Current Centers for Disease Control and Prevention (CDC) guidelines reflect critical therapeutic updates designed to combat antimicrobial resistance and optimize cure rates.
Important
The CDC STI guidelines recommend oral doxycycline (100 mg twice daily for 7 days) as first-line therapy for uncomplicated urogenital Chlamydia trachomatis , replacing single-dose azithromycin. For uncomplicated Neisseria gonorrhoeae , ceftriaxone 500 mg intramuscular monotherapy is standard for patients weighing under 150 kg.
Chlamydia trachomatis
Chlamydia trachomatis is the most frequently reported bacterial STI in the United States. Infection is predominantly asymptomatic (up to 70–80% of women), serving as a silent reservoir for upper genital tract disease.
Screening & Diagnostics
Screening: Annual screening is recommended for all sexually active women under 25 years. Women aged 25 and older require annual screening if high-risk factors exist (new or multiple partners, concurrent STI, inconsistent barrier use). Universal screening is mandated at the first prenatal visit, with third-trimester retesting for high-risk patients.
Diagnostics: Nucleic Acid Amplification Testing (NAAT) from a vaginal swab (patient- or clinician-collected) is the gold standard. First-catch urine and endocervical swabs are acceptable alternatives.
Treatment & Surveillance
First-Line Regimen: Oral doxycycline 100 mg twice daily for 7 days.
Alternative / Pregnancy: Oral azithromycin 1 g single dose is reserved for pregnancy (doxycycline is contraindicated) or documented severe non-adherence.
Surveillance: All patients require rescreening at 3 months post-treatment due to high reinfection rates. A test-of-cure (TOC) via NAAT at 4 weeks is indicated only during pregnancy or when using alternative regimens.
Neisseria gonorrhoeae
Neisseria gonorrhoeae is a fastidious Gram-negative diplococcus infecting mucosal columnar and transitional epithelium, presenting as purulent cervicitis, urethritis, or proctitis.
Diagnostics & Pharmacotherapy
Diagnosis relies on NAAT. Routine dual therapy with azithromycin has been discontinued to avoid promoting macrolide resistance.
Weight < 150 kg: Ceftriaxone 500 mg intramuscular (IM) in a single dose.
Weight >= 150 kg: Ceftriaxone 1,000 mg (1 g) IM in a single dose.
Chlamydia Co-Infection: If chlamydia has not been excluded by NAAT, add oral doxycycline 100 mg twice daily for 7 days (or azithromycin 1 g if pregnant).
Follow-Up: Uncomplicated gonorrhea treated with ceftriaxone does not require a test-of-cure; repeat screening is recommended at 3 months.
Syphilis (Treponema pallidum)
Syphilis is a systemic venereal infection caused by the spirochete Treponema pallidum . Untreated disease progresses through distinct clinical stages.
Stage Clinical Features Diagnostic Findings
Primary Solitary, indurated, painless ulcer (chancre); painless adenopathy Darkfield microscopy; reactive serology (may lag)
Secondary Non-pruritic maculopapular rash on palms/soles; condylomata lata Peak non-treponemal titers (RPR >= 1:32); reactive treponemal test
Latent Asymptomatic seropositivity (Early: <1 yr; Late: >1 yr or unknown duration) Reactive serology without active lesions; normal CSF
Tertiary Gummatous necrosis, aortic aneurysm, aortitis, late neurosyphilis Reactive treponemal serology; variable non-treponemal titers
Diagnostic Algorithms
Traditional Algorithm: Initial non-treponemal screening (RPR or VDRL) detecting anticardiolipin antibodies. Quantitative titers monitor disease activity and therapeutic response (a fourfold decrease indicates cure). Reactive screens require confirmation with a specific treponemal assay (TP-PA or FTA-ABS). Biological false positives occur with pregnancy, lupus, and viral infections.
Reverse Sequence Algorithm: Automated treponemal immunoassay (EIA/CIA) performed first. If reactive, reflex to quantitative RPR. Discordant results are arbitrated by a second treponemal assay (TP-PA).
Screening in Pregnancy: CDC recommends syphilis serology for every pregnant patient at the first prenatal visit. Because congenital syphilis rose sharply, ACOG (2024) now recommends universal rescreening in the third trimester (ideally around 28 weeks) and again at delivery.
Pharmacotherapy & Reactions
Primary, Secondary, Early Latent: Benzathine penicillin G 2.4 million units IM in a single dose.
Late Latent / Unknown Duration: Benzathine penicillin G 2.4 million units IM weekly for 3 consecutive weeks (total 7.2 million units). Missed doses exceeding 14 days in non-pregnant patients (>7–9 days in pregnancy) require restarting the series.
Pregnancy & Allergy: Penicillin is the only effective agent during pregnancy. Allergic pregnant patients must undergo desensitization and receive benzathine penicillin G.
Jarisch-Herxheimer Reaction: An acute systemic febrile reaction (fever, chills, headache) occurring 2–24 hours following spirochetal lysis. It is managed with antipyretics. In pregnancy, it may precipitate uterine contractions or fetal heart rate decelerations.
Pelvic Inflammatory Disease (PID)
Pelvic inflammatory disease is an ascending, polymicrobial infection extending from the endocervix to the endometrium, fallopian tubes, and pelvic peritoneum, involving C. trachomatis , N. gonorrhoeae , Mycoplasma genitalium , and anaerobes.
Clinical Diagnostic Criteria
To prevent irreversible tubal scarring, clinicians must initiate empiric therapy in sexually active women with lower abdominal/pelvic pain who exhibit at least one minimum clinical criterion on bimanual exam:
- Cervical motion tenderness ("chandelier sign")
- Uterine tenderness
- Adnexal tenderness
Supportive criteria include oral temperature >38.3 deg C (101 deg F), abnormal cervical mucopurulent discharge or friability, abundant WBCs on wet mount, elevated ESR or C-reactive protein, and positive gonococcal or chlamydial laboratory results.
Pharmacotherapy & Sequelae
Outpatient Regimen: Ceftriaxone 500 mg IM single dose (<150 kg) PLUS oral doxycycline 100 mg twice daily for 14 days PLUS oral metronidazole 500 mg twice daily for 14 days. Metronidazole ensures coverage against anaerobes and bacterial vaginosis.
Inpatient Criteria: Pregnancy, surgical emergencies unexcluded (appendicitis), severe illness/vomiting, tubo-ovarian abscess (TOA), or failure of outpatient therapy after 48–72 hours. Inpatient regimens include IV cefotetan or cefoxitin plus doxycycline.
Long-Term Sequelae: Tubal factor infertility (~8% after 1 episode, ~20% after 2, ~40% after 3), 7- to 10-fold increased ectopic pregnancy risk, and chronic pelvic pain.